Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.42 -1.03 (-2.13%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗

September 09, 2025

Novartis agreed to buy a cardiovascular-focused biotech company

Via Investor's Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗

September 09, 2025

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.

Via Investor's Business Daily

1 Reason Every Investor Should Know About Novo Nordisk (NVO) ↗

September 08, 2025

The company could be on the verge of turning the tide in the battle over weight loss drugs.

Via The Motley Fool

Ozempic Is The New Botox And Big Pharma Is Printing Billions ↗

September 08, 2025

Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion.

Via Benzinga

FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List ↗

September 07, 2025

FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments.

Via Benzinga

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗

September 03, 2025

Via Stocktwits

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗

September 05, 2025

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

Via Benzinga

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Viking aims to enter the billion-dollar weight loss drug market.

Via The Motley Fool

Where Will Eli Lilly Be in 3 Years? ↗

September 04, 2025

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

Via The Motley Fool

Topics Intellectual Property

The Problem With Weight Loss Stocks ↗

September 03, 2025

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Via The Motley Fool

Topics Economy

After Copycat Boom, China's Drugmakers Target Global Generics ↗

September 03, 2025

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

Via Benzinga

Topics Supply Chain

Should You Buy Novo Nordisk Stock Now or Wait? ↗

September 03, 2025

NVO stock is down 60% over the past 12 months.

Via The Motley Fool

Is Novo Nordisk Stock a Buy Now? ↗

September 03, 2025

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

Via The Motley Fool

Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades ↗

September 03, 2025

Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗

September 02, 2025

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Via Benzinga

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

August 30, 2025

NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

Via Chartmill

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

Via The Motley Fool

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda ↗

August 28, 2025

Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.

Via Benzinga

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗

August 28, 2025

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

Via Benzinga

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today? ↗

August 28, 2025

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop...

Via Stocktwits

FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk ↗

August 28, 2025

Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs.

Via Investor's Business Daily

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗

August 28, 2025

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.

Via Investor's Business Daily

UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears ↗

August 28, 2025

Patients in UK struggle to obtain Mounjaro drug due to high demand, sharp price increase. Shortages causing stress and health risks.

Via Benzinga

Stevens Capital Closes Out Position in Eli Lilly ↗

August 28, 2025

Via The Motley Fool

2 Dividend Stocks to Hold for the Next 10 Years ↗

August 28, 2025

These stocks offer more than just dividends.

Via The Motley Fool

Topics Economy

2 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade ↗

August 28, 2025

It doesn't take much to get your money to start working for you on Wall Street.

Via The Motley Fool

Market Movers: Unpacking the Forces Behind Recent Stock Swings

August 27, 2025

The financial markets have been a dynamic arena recently, showcasing significant and often dramatic movements in individual stock valuations. These shifts are not random but are deeply rooted in...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

Headline News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today